This is a knockout-validated antibody summary, based on the publications "The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level", as cited below [1], "ARID1A Spatially Partitions Interphase Chromosomes" for western blot (figure 1b) [2], "Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma" for western blot knockout validation (figure 1c, e1b, e2h) [3], and "Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy" for western blot knockout validation (figure s2a) [4]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

[enlarge]

Figure 1. Representative immunoblot of cell lysates from ARID1A CRISPR knockout or control cells derived from OVCA429. Two CRISPR knockout clones are shown. From [1].

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: ARID1A/BAF250A

Catalog number: 12354

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to residues surrounding Gly1293 of human ARID1A/BAF250A protein. Reacts with human, mouse, rat, and monkey. Suitable for western blot and immunohistochemistry (paraffin).

Western blot

Control and ARID1A knockout OVCA429 cells. Cell lysates were prepared using SDS lysis buffer (50 mm Tris-HCl pH 7.5, 150 mm NaCl, 1% SDS, 1 mm EDTA) with freshly added 1 mm DTT and protease inhibitors (150 μm PMSF, 1 μg/ml Pepstatin A, and 1 μg/ml Leupeptin).

1:1,000 dilution

1:50,000 dilution peroxidase-conjugated anti-rabbit IgG (Sigma-Aldrich, cat. no. A0545).